Vincenzo Brescia Morra

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Ludwig Kappos, Amit Bar‐Or, Bruce Cree et al. · The Lancet · 2018 · 896 citations

Neurological Disorder, Clinical Neurology, Clinical Trials +9

Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome

Enrico Millefiorini, Claudio Gasperini, Carlo Pozzilli et al. · Journal of Neurology · 1997 · 271 citations

Relapsing-remitting Multiple Sclerosis, Neurological Disorder, Medicine +8

Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing–remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study

Francesco Patti, María Trojano, Stefano Bastianello et al. · Multiple Sclerosis Journal · 2009 · 189 citations

Grey matter loss in relapsing–remitting multiple sclerosis: A voxel-based morphometry study

Anna Prinster, Mario Quarantelli, Giuseppe Orefice et al. · NeuroImage · 2005 · 175 citations

Grey Matter Loss, Neurological Functioning, Neurological Disorder +9

Effects of Bacille Calmette-Guérin after the first demyelinating event in the CNS

Giovanni Ristori, Silvia Romano, Stefania Cannoni et al. · Neurology · 2013 · 153 citations